Galmed Pharmaceuticals Ltd. · NASDAQ:GLMD

Galmed Pharmaceuticals — Technical Presentation (November 2021)

13 slides from Galmed Pharmaceuticals's technical presentation, Nov 8, 2021

  1. Slide 1: Clinical antifibrotic effect of Aramchol: histology and convergent biomarker data

    @Galmed Pharmaceuticals Clinical antifibrotic effect of Aramchol™: histology and convergent Leveraging Science biomarker data Ae Prof. Vlad Ratziu, Professor of Hepatology, Sorbonne Université, ARMOR study co- principal investigator November 2021

  2. Slide 2: Safe Harbor and Disclaimer Statement

    “4 Safe Harbor and Disclaimer Statement “his pesraton oti orwardslirg satan soi our eects, baler ating amore ter ies. ou padi dewloper ls, Dating ssn ri ot wing fomwaoirg temers can beldeiied byte we loeaocing wey sus tele peter po "athe ante otha neareso ete vrorsa ee ors ober caste worse bythe tha

  3. Slide 3: ARMOR - Ph3 Study Design & Clinical Rationale for The Open Label Part

    @@ ARMOR - Ph3 Study Design & Clinical Rationale for The Open Label Part + Designed to provide effect size of higher (Carica) dose of Aramchol 300mg BID (153% mam [— severe. ; elevation in exposure) and optimize treatment duration for Aramchol”™ * Arigorous and robust blinded reading te process incl

  4. Slide 4: Baseline Characteristics

    Baseline Characteristics ‘ARMOR study eae ae ers ineen 250, Wee ime 20, a(n} ean #50 ‘eoieny Late breaker AASLD aassas 150559, ara 1195) 305%) p04 165) ‘ARMORStudy Females, fae yrs incon), Well (msn 250), gma (mean +50, thier |ARCON cohort (e339) 105 (77794 nese 294 se03%) nos 2a7391 368051 2855) ai

  5. Slide 5: A Substantial Effect on Fibrosis Improvement Based on Histology is Demonstrated

    A Substantial Effect on Fibrosis Improvement Based on Histology is Demonstrated € inthe First 20 Patients (Late breaker AASLD Cohort) with Post-baseline Biopsy a PA on ‘sg npn. om iB a hy Les mga 18 40 = © secre 551 we 1S serene * nt by 21 stage and only a single patient had fibrosis worsening; in 5

  6. Slide 6: Fibrosis Stage at Baseline and Post-Baseline

    Fibrosis Stage at Baseline and Post-Baseline Fibrosis Stage at BL 3 (1595) 4 (20%) FL OFZ @FB ‘At baseline 659 of patients had fibrosis stage ‘At baseline 15% of patients had fibro Fibrosis Stage After Treatment 2 (1056) 7 (35%) 6 (30%) FO @FI OFZ @F3 reduced to 25% at post-baseline eased to 45% (FO

  7. Slide 7: Change from Baseline in ALT & AST - Late breaker AASLD Cohort and ARCON Cohort

    @@ Change from Baseline in ALT & AST - Late breaker AASLD Cohort and ARCON Cohort hang tom inn at UA hong om inn 8 0

  8. Slide 8: Change from Baseline in Fib-4 - Late breaker AASLD Cohort and ARCON Cohort

    @@ Change from Baseline in Fib-4 - Late breaker AASLD Cohort and ARCON Cohort

  9. Slide 9: Change from Baseline in ProC-3 Late breaker AASLD Cohort and ARCON Cohort

    Change from Baseline (absolute and pet. change) in ProC-3 Late breaker AASLD Cohort and ARCON Cohort Procollagen 3 N-Terminal Propeptide - Mean Baseline 48.8 wg/L — q t | | :

  10. Slide 10: Summary of Results

    Summary of Results @Galmed

  11. Slide 11: Aramchol in patients with nonalcoholic steatohepatitis: phase 2b trial

    med ARTICLES Bice Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial V.Ratziu® "©; L de Guevara, R, Safad, F Poordad’ Fuster. Flores-Figueroat, M. Arcese”, ‘Anna L Fracanzan® D, Ben Bashat!, K. Lackner, T, Gorfine", S Kadash R, Oren,

  12. Slide 12: Conclusions

    @@) Conclusions + Data add to body of evidence from prior studies demonstrating the benefit of Aramchol”™ for patients with histologically confirmed NASH and fibrosis, and provides clinical support to the hypothesis that a higher daily dose will result in improved clinical benefit + Data support the

  13. Slide 13: Galmed Pharmaceuticals

    @Galmed Pharmaceuticals

Galmed Pharmaceuticals — Technical Presentation (November 2021) on 6ix